HOME > 상세정보

상세정보

3개 대학병원 항암치료 환자의 진료비 현황 및 진료비 변이 요인에 관한 연구 : 탁솔 항암치료 환자를 중심으로

3개 대학병원 항암치료 환자의 진료비 현황 및 진료비 변이 요인에 관한 연구 : 탁솔 항암치료 환자를 중심으로 (1회 대출)

자료유형
학위논문
개인저자
이미영 李美英
서명 / 저자사항
3개 대학병원 항암치료 환자의 진료비 현황 및 진료비 변이 요인에 관한 연구 : 탁솔 항암치료 환자를 중심으로 = (A)study on the status quo and variation of medical cost for chemotherapy patients in three university hospitals : focusing on Taxol chemotherapy patients / 李美英.
발행사항
서울 :   고려대학교 ,   2005.  
형태사항
[ⅷ], 88 p : 삽도 ; 26 cm.
학위논문주기
학위논문(석사) -- 고려대학교 보건대학원 : 보건정책 및 병원관리학과 , 2005.2
학과코드
0510   6H3   33  
일반주기
지도교수 : 윤석준  
비통제주제어
Medical cost , Chemotherapy , Variation , Response , Taxol , Anti-cancer medicines ,,
000 00991namccc200229 k 4500
001 000045200779
005 20100806071623
007 ta
008 051027s2005 ulka m AC 000a kor
040 ▼a 211009 ▼d 211009
085 ▼a 0510 ▼2 KDCP
090 ▼a 0510 ▼b 6H3 ▼c 33
100 1 ▼a 이미영 ▼g 李美英
245 1 0 ▼a 3개 대학병원 항암치료 환자의 진료비 현황 및 진료비 변이 요인에 관한 연구 : ▼b 탁솔 항암치료 환자를 중심으로 = ▼x (A)study on the status quo and variation of medical cost for chemotherapy patients in three university hospitals : focusing on Taxol chemotherapy patients / ▼d 李美英.
260 ▼a 서울 : ▼b 고려대학교 , ▼c 2005.
300 ▼a [ⅷ], 88 p : ▼b 삽도 ; ▼c 26 cm.
500 ▼a 지도교수 : 윤석준
502 0 ▼a 학위논문(석사) -- ▼b 고려대학교 보건대학원 : ▼c 보건정책 및 병원관리학과 , ▼d 2005.2
653 ▼a Medical cost ▼a Chemotherapy ▼a Variation ▼a Response ▼a Taxol ▼a Anti-cancer medicines
900 ▼a Lee, Mi Young
900 ▼a 윤석준 , ▼e 지도교수

전자정보

No. 원문명 서비스
1
3개 대학병원 항암치료 환자의 진료비 현황 및 진료비 변이 요인에 관한 연구 : 탁솔 항암치료 환자를 중심으로 (9회 열람)
PDF 초록

소장정보

No. 소장처 청구기호 등록번호 도서상태 반납예정일 예약 서비스
No. 1 소장처 의학도서관/보존서고1/ 청구기호 0510 6H3 33 등록번호 133003426 도서상태 대출가능 반납예정일 예약 서비스 B

컨텐츠정보

초록

A study on the status quo and variation of medical cost for chemotherapy patients 
in three university hospitals. 
-Focusing on Taxol chemotherapy patients-    

LEE MI YOUNG
Supervising Professor : Yoon Seok Jun
Department of Health Policy and Hospital Management
Graduate School of Public Health, Korea University


  In recent times cancer has ranked as the number one cause of decease in Korea and its occurrence rate also has been on an increasing trend. Since 2000 the development of new high price anti-cancer medicines, which amount to tens of million won has been increasing. Consequently it is expected that the cost of medicine, which accounts for the largest proportion in the total cost of  chemotherapy, will increase rapidly. A variety of chemotherapy - hundreds kinds of anti-cancer therapies are being carried out lately- has made the medical variation more crucial compared with other diseases.  
It can be pointed out, however, that there has not been sufficient studies on the cost of chemotherapy and anti-cancer medicines and the response to its therapy among the domestic research involving cancer so far. In accordance with such a background this study aims at presenting the basic data for effective and economic chemotherapy in medical institutions and public health care policy. It is also expected that this study will be able to be used as the basic data for the introducing the private medical care insurance.  
  For this purpose, this study analyzed the status quo and variation of medical cost focusing on Taxol chemotherapy patients, which is most frequently prescribed and has comprehensive indication for the use of the medicine, based on the recent two years' data. When chemotherapy is standardized with Taxol chemotherapy, the variation factors of medical cost such as the kind of cancer, medical institutes, cancer stage, and the cost depending on the response of the therapy are analyzed by several kinds of statistic methods. 

  According to the results of the study, although the same anti-cancer medicines were used, there were differences of medical cost depending on the kind of cancer and medical institutions. In other words, medical cost was variated by the attribute of medical service suppliers. The analysis of the medical cost depending on the reaction of therapy for each kind of cancer showed that when the response of therapy was good, the medical cost was relatively low, whereas when the response of therapy was negative, the medical cost was high. This seems to result from the different starting time of therapy and the seriousness of the patients.
 
  Chemotherapy is an emergent situation for the patients, therefore, it should be an effective and economic therapy. And regarding the different medical cost of each medical institution despite using the same anti-cancer medicines, the standard indication to chemotherapy should be enacted and be utilized with the establishment of the public health care policy. 


key words : medical cost, chemotherapy, variation, response, taxol, anti-cancer medicines